Federal Trade Commission Acts for First Time Against Stem Cell Clinics

December 26, 2018

(Pew Charitable Trusts) – The Federal Trade Commission (FTC) recently announced a settlement with a physician in California to resolve charges that the two clinics he controlled engaged in deceptive advertising to promote  unproven stem cell-based therapies. This case represents the first enforcement action by the FTC—which protects consumers from false and misleading advertisements—to stop the promotion of stem cell treatments that have not been approved by the Food and Drug Administration (FDA).

Recommended Reading